You're asking about a compound called **1-[2-furanyl(oxo)methyl]-2-benzo[cd]indolone**. Let's break down what it is and why it's important for research.
**Structure and Naming:**
* **1-[2-furanyl(oxo)methyl]-2-benzo[cd]indolone** is a complex organic molecule with a very specific structure. It contains several functional groups, including:
* **Benzo[cd]indolone:** This is a bicyclic structure derived from indolone (a nitrogen-containing ring system).
* **Furan:** A five-membered ring containing an oxygen atom.
* **Oxo** (carbonyl group): A double-bonded oxygen atom attached to a carbon atom.
* **Methyl:** A single carbon atom with three hydrogen atoms attached.
**Importance in Research:**
The reason why this specific compound is important for research is not immediately obvious from its name. Here's why we need more context:
* **Potential Biological Activity:** Many complex organic molecules with unique structures like this one have the potential to exhibit biological activity. This could include:
* **Anti-cancer properties:** Compounds with specific chemical structures can interact with cancer cells and interfere with their growth or survival.
* **Anti-inflammatory effects:** They might be able to modulate the immune system and reduce inflammation.
* **Antimicrobial activity:** They could inhibit the growth of bacteria or other microorganisms.
* **Drug Development:** Researchers are constantly seeking new compounds that could be developed into effective drugs.
* **Mechanism of Action:** Understanding how this compound interacts with biological systems is crucial. Researchers might study:
* **Target proteins:** What specific proteins in the body does the compound bind to?
* **Cellular pathways:** How does the compound affect different cellular processes?
**Where to Find More Information:**
To learn more about the specific research involving 1-[2-furanyl(oxo)methyl]-2-benzo[cd]indolone, you'll need to look for scientific publications or databases related to the following:
* **Chemical Synthesis:** How is the compound prepared and purified?
* **Biological Activity:** Has the compound been tested for any biological effects?
* **Preclinical Studies:** Have any preclinical studies (in animals) been conducted to investigate its potential therapeutic value?
* **Clinical Trials:** Is the compound currently being tested in human trials?
**Searching for Research:**
* **PubMed:** A database of biomedical literature. Search for the compound name and related keywords.
* **SciFinder:** A comprehensive chemical database that can be used to search for publications and patents related to the compound.
* **Google Scholar:** A search engine specifically for scholarly publications.
By researching using these resources, you can find the most up-to-date information on the research surrounding this specific compound and its potential significance.
ID Source | ID |
---|---|
PubMed CID | 2236435 |
CHEMBL ID | 1524294 |
CHEBI ID | 109114 |
Synonym |
---|
HMS1600O01 |
AKOS002376654 |
SDCCGMLS-0027712.P002 |
MLS000100219 , |
1-(2-furoyl)benzo[cd]indol-2(1h)-one |
smr000082187 |
CHEBI:109114 |
HMS2284P10 |
1-[2-furanyl(oxo)methyl]-2-benzo[cd]indolone |
1-(2-furoyl)benzo[cd]indol-2-one |
bdbm40893 |
1-(furan-2-carbonyl)benzo[cd]indol-2-one |
cid_2236435 |
1-(furan-2-ylcarbonyl)benzo[cd]indol-2-one |
CHEMBL1524294 |
AQ-390/43490644 |
Q27188176 |
SR-01000298737-1 |
sr-01000298737 |
Class | Description |
---|---|
indolyl carboxylic acid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.1220 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 35.4813 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 35.4813 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
TDP1 protein | Homo sapiens (human) | Potency | 14.9692 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
DNA polymerase beta | Homo sapiens (human) | Potency | 25.1189 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0398 | 16.7842 | 39.8107 | AID995 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 5.3233 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 25.1189 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 14.1254 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 6.5131 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 10.0000 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.3900 | 6.5441 | 29.1200 | AID1275 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |